PHVS

Pharvaris BV

PHVS, USA

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

https://pharvaris.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PHVS
stock
PHVS

Pharvaris (NasdaqGS:PHVS): Reassessing Valuation After RAPIDe-3 Phase 3 Success and Deucrictibant Commercial Progress simplywall.st

Read more →
PHVS
stock
PHVS

Pharvaris (NASDAQ:PHVS) Rating Lowered to Sell at Wall Street Zen Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$37.8857

Analyst Picks

Strong Buy

6

Buy

2

Hold

0

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

4.82

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-11.89 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-10.96 %

Low ≤ 2%

High ≥ 10%

Debt to Equity

-

Very High

0.09

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 10.31% of the total shares of Pharvaris BV

1.

Fidelity Growth Compy Commingled Pl S

(2.6882%)

since

2025/07/31

2.

Fidelity Growth Company Fund

(1.9686%)

since

2025/07/31

3.

Fidelity Select Health Care

(1.1961%)

since

2025/07/31

4.

Fidelity Small Cap Growth

(1.1323%)

since

2025/06/30

5.

Fidelity Advisor Health Care I

(0.7701%)

since

2025/07/31

6.

Fidelity Growth Company K6

(0.5985%)

since

2025/07/31

7.

Fidelity Series Growth Company

(0.5575%)

since

2025/07/31

8.

Fidelity Small Cap Growth K6

(0.4318%)

since

2025/06/30

9.

Fidelity VIP Health Care Initial

(0.1762%)

since

2025/07/31

10.

Fidelity Select Biotechnology

(0.1638%)

since

2025/07/31

11.

iShares MSCI EAFE Small-Cap ETF

(0.1141%)

since

2025/08/31

12.

iShares Core MSCI EAFE ETF

(0.0858%)

since

2025/08/31

13.

State St Gbl Sm Cp Eq ex-US Indx NL Cl A

(0.0736%)

since

2025/08/31

14.

iShares MSCI EMU Small Cap ETF EUR Acc

(0.0655%)

since

2025/08/31

15.

Xtrackers MSCI Eur Small Cap ETF 1C

(0.064%)

since

2025/07/31

16.

Amundi MSCI EMU SmCapESGBrdTrnstnETFDIS

(0.0624%)

since

2025/08/29

17.

Fidelity Nasdaq Composite Index

(0.0533%)

since

2025/07/31

18.

UBS MSCI EMU Small Cap ETF EUR dis

(0.0428%)

since

2025/08/29

19.

iShares MSCI Netherlands ETF

(0.0373%)

since

2025/08/31

20.

Nationwide International Sm Cp R6

(0.0305%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

-0.6418

Latest Release

Date

2025-09-30

EPS Actual

-0.6

EPS Estimate

-0.6755

EPS Difference

0.0755

Surprise Percent

11.1769%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.